Over-expression of PAD4 has been reported in numerous cancer types [43–50], in contrast to benign tumours and non-tumour inflamed tissues that do not exhibit high levels of PAD4 expression, suggesting its association with cancer progression and its potential as a cancer drug target [43]. This evidence concerns the gene PADI4 and neoplasm.